Skip to main content

Table 1 Previous reports on adverse events associated with tranexamic acid in patients on maintenance dialysis

From: Oral tranexamic acid combined with low molecular weight heparin only during dialysis sessions successfully controlled chronic disseminated intravascular coagulation associated with aortic aneurysm and aortic dissection in a dialysis patient: a case report with literature review

Author

Patient age and sex

Mode of dialysis therapy

Dosage and route of administration (weight-based dosing)

Adverse events

Management

Days required for recovery

Outcome

Kitamura et al. [20]

56, male

Hemodialysis

2 g daily IV × approximately 2 weeks

Visual loss

Tranexamic acid discontinuation

2–3 days

Partial recovery with residual visual impairment in dark places

Hui et al. [21]

61, male

Peritoneal dialysis

2 g daily PO × 6 days

Multifocal myoclonus

Tranexamic acid discontinuation

4 days

Complete recovery

Ma et al. [18]

57, male

Peritoneal dialysis

1 g IV [< 15 mg/kg]

Disorientation, upper extremity myoclonus, and visual disturbance

Tranexamic acid discontinuation

3 days

Complete recovery

Ma et al. [18]

50, female

Peritoneal dialysis

6 g IV (4.5 g IV during operation and another 1.5 g IV postoperatively) [< 120 mg/kg within 12 h]

Disorientation, generalized tonic-clonic convulsion

Tranexamic acid discontinuation, continuous renal replacement therapy

1 week

Complete recovery

Ma et al. [18]

61, male

Peritoneal dialysis

3 g daily PO × 3 days [< 45 mg/kg per day]

Slurring of speech, upper extremity myoclonus, unsteady gait, and visual disturbance

Tranexamic acid discontinuation

3 days

Complete recovery

Fuah et al. [22]

65, male

Hemodialysis

2 g IV (1 g IV × 2 doses over 5 h)

Generalized tonic-clonic convulsion

Tranexamic acid discontinuation, intravenous diazepam 5 mg for the acute treatment of second seizure

1 day

Complete recovery

  1. IV intravenous, PO per oral